RNA based therapeutics has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, AIDS, Tuberculosis and certain cardiovascular conditions. Despite being in the clinical research phase, the RNA based therapeutics is been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. RNAi technology works by causing destruction of specific mRNA molecules; whereas, antisense technology works by synthesizing strand of RNA from known gene sequence. These newly synthesized RNA strands then itself binds to mRNA and make mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market.
The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field. Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies. Quark Pharmaceuticals, Inc. (USA), Alnylam Pharmaceuticals, Inc. (USA), Dicerna Pharmaceuticals, Inc. (USA), Tekmira Pharmaceuticals Corp. (Canada), Benitec Biopharma Limited (Australia), Genzyme Corporation (USA), ISIS pharmaceuticals Inc (USA), Silence Therapeutics PLC (UK) and Cenix BioScience GmbH (Germany) are some of the key players in this market. ISIS pharmaceuticals, Inc. (USA) has focused its research activities on antisense technology and developed antisense therapeutics, namely Mipomersen and Fomivirsen. This therapeutics is commercially available in the market and marketed as Kynamro and Vitravene respectively. Quark, Alnylam and silence therapeutics are other major players of this market with strong research pipeline in RNA based therapeutics.
RNA based therapeutics market is segmented into technology, application, end-users and geography. Technology segment is further categorized as enabling technologies and enabled technologies. The segment of enabling technologies comprises of Microarrays, Labeling, Purification, Linear amplification, qRT-PCR and Inhibition; whereas, enabled technologies includes RNA interference technology (RNAi) and RNA antisense technology. Enabled technologies account for largest market share due to their potential use in therapeutics. The market for RNA based therapeutics is dominated by RNA interference technology as numerous companies have exhibited their interest to develop the RNA drugs using RNAi technology. RNA based therapeutics have wide applications covering variety of chronic conditions such as Cardiovascular, Kidney Diseases, Oncology, Infectious diseases, Metabolic disorders and Others. The pipeline research is concentrated towards oncology and infectious diseases due to their high prevalence and failure of existing treatment to effectively treat these conditions. The end user market is segmented into research, therapeutics and diagnostics. Currently, research and diagnostics segments are largely exploring the RNA technologies and therapies for the commercialization of RNA drugs.
Geographically, RNA based therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Potential regions of the respective geographies are strategically analyzed to provide country wise focus on RNA research activities. North America dominates the RNA based therapeutics followed by Europe and Asia-Pacific. The key market players belong to North America and are conducting extensive research to commercialize the therapeutics. Moreover, the growth in North America and Europe is primarily driven by substantial investment on research, advancement in RNA platform technologies, government support and availability of suitable infrastructure to develop the novel RNA based therapies. However, business dynamics in Asia-pacific is anticipated to offer tremendous opportunities to major players of this market as cost of clinical research is less in this region as compared to North America and Europe.
KEY MARKET SEGMENTS
RNA based therapeutics market is segmented into four major categories such as Technology, Application, End Users and Geography.
MARKET BY TECHNOLOGY
MARKET BY APPLICATION
MARKET BY END USERS
MARKET BY GEOGRAPHY